KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction.

Sara R O Siqueira, Maria A Pabon, Muthiah Vaduganathan, Brian L Claggett, Carolyn S P Lam, Mikhail N Kosiborod, Rudolf A de Boer, Sanjiv J Shah, James C Fang, Akshay S Desai, Pardeep S Jhund, Silvio E Inzucchi, Felipe Martinez, Adrian F Hernandez, Magnus Petersson, John J V McMurray, Scott D Solomon, Orly Vardeny

JACC Heart Fail 13(10) 102585

PMID40834567
PMCID-
DOI10.1016/j.jchf.2025.102585
发表日期2025-08-20
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: Patients with heart failure with improved ejection fraction (HFimpEF) remain understudied and face residual risks comparable with those with a left ventricular ejection fraction (LVEF) consistently >40% (no prior heart failure with reduced ejection fraction). The implications of achieved LVEF after improvement on prognosis and treatment response remains unclear. OBJECTIVES: This study examines whether the degree of LVEF improvement influences prognosis and the therapeutic effects of dapagliflozin in HFimpEF. METHODS: The DELIVER trial randomized patients with heart failure and LVEF >40% to dapagliflozin or placebo, including those with HFimpEF. In the HFimpEF subset, we examined the association between baseline LVEF (≤49% [reference group], 50%-59%, and ≥60%) and the primary outcome (worsening HF or cardiovascular death) and whether the degree of LVEF improvement modified the treatment response to dapagliflozin. RESULTS: Of 6,263 participants, 1,151 (18%) had HFimpEF: 624 (54%), 328 (29%), and 199 (17%) had improved LVEF at baseline of ≤49%, 50%-59%, and ≥60%, respectively. Over a median follow-up of 2.3 years, primary outcome rates (per 100 person-years) in HFimpEF vs LVEF consistently >40% were 9.9 vs 10.5 (≤49%), 6.7 vs 8.4 (50%-59%), and 9.3 vs 7.5 (≥60%). Dapagliflozin safely and consistently reduced the risk of the primary outcome across LVEF groups (P for interaction = 0.19). CONCLUSIONS: In patients with HFimpEF, the efficacy and safety of dapagliflozin in reducing cardiovascular death or worsening HF events were consistent irrespective of the degree of LVEF improvement before enrollment, including in those who achieve an LVEF ≥60% who appear to face significant residual risks of clinical events. (Dapagliflozin Evaluation to Improve the LIVEs of Patients With Preserved Ejection Fraction Heart Failure [DELIVER]; NCT03619213).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。